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A high pM anion exchange chromatographic (HPAEC) system for the separation of isomcric sialo-oligosaccharide products was bevrlopcd. 
Employing this system, using Gal~I~GlcNA~I-32Manal~(lMa~I~lcNAc as a substrate, a Gal/?I+4GlcNAc-R a;2+3-sialylvansfense 
activity was dctcctcd for the first time in human liver. This activity is expressed together with the prevalent a2-&-sialyltransfcrasc. Funhctmorc, 
in addition to the major a2~3-sialyltMnsf~rase, a low but distinct activity of a2+fi-sinlyltransferasc was dctcctcd in human placenta. This activity 
could not be found by methods based on mcthylation analysis or high resolution NMR spectroscopy. It is concluded that HPAEC, in oxnbination 
with the use of the pentasaccharide as an acceptor substrate. issuited for the specific detection of minor, Gal,% _p4GlcNAc_spccific siatjitransferasc 
aclivides. 
Sialyltransferasc; Sialic acid; High pH irnion exchange chromatography (HPAEC); Pulsed ampcromctric detection (PAD); Human liver; Human 
placenta 
1. 1NTRODUCTION 
Individual IV-glycoproteins from various tissues and 
species often contain both a2+3- and a2+6-linked 
sialic acid (NeuAc) at the Gal,Bl+4GlcNAc termini of 
their complex-type glycans [l-S]. On the other hand, 
many glycoproteins are known to contain NeuAc in 
only one of these linkage types [1,9-141. Several studies 
from this and other laboratories have shown that the 
NeuAc linkage type generally can be explained from the 
activities of the CMP-NeuAc:Gal~1+4GlcNAc-R 
a2+3- (a3-sialyltransferase) or a2+6-sialyltransferase 
(cr6-sialyltransferase) in the corresponding tissues [15 
I?]. However, no a3-sialyltransferase activity has been 
identified in human liver to date, although structural 
studies have revealed that the tri- and tetra-antennary 
glycans of several glycoproteins synthesized by this tis- 
sue do contain terminal NeuA~2-+3Gal/?l+4GlcNAc 
sequences (references cited in [2,3]). 
Previously, a Gal/?l+3(4)GlcNAc-R a2+3-sialyl- 
transferase had been detected in rat liver [l&19]. Al- 
though this enzyme prefer5 type 1 chain 
(Gak%-+3GlcNAc) acceptors, it was also found to act 
on acceptors with type 3 termini (Gal/?l+4GlcNAc), 
albeit with lower eiriciency [XI”. Nevertheless, enzyme- 
catalyzed transfer of ?kuAc to C-3 of the terminal Gal 
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residues of asialo-a,-acid glycoprotein could not be de- 
tected by methylation analysis of the product formed 
with rat liver [16,17]. Simiiarly no a3-sialyltransferase 
activity was found in human liver, when the product 
formed with Galpl+4GlcNAc (IV-acetyllactosamine) 
as an acceptor was analyzed by MPLC 1211. 
In an attempt o improve the detection method for 
a3- and a6-sialyltransferases we developed a procedure 
using a type 2 chain-based pentasaccharide, 
Ga~l+4GlcNAc/?1~2Manal~6Man/?l+4GlcNAc 
[22], as an acceptor, analyzing the reaction product by 
high pH anion exchange chromutography (HPAEC) 
with ~;ulxd amperometric detection (PAD). The 
method appeared to have a greatly improved sensitivity 
as it allowed the specific detection of small amounts of 
product in the presence of an excess of isomeric mate- 
rial. Using this procedure, we were able to detect a3- 
sialyltransferase activity in human liver. Moreover, 
when the method was applied to human placenta, alow 
but distinct a6sialyltransferase activity was found in 
addition to the major a3-sialyltransfcrase known to be 
present in this tissue [16]. 
2. MATERIALS AND METHODS 
2. I. Muterids 
CMP-[‘WNeuAc (specific radioactivity 28,200 Ci/mol) was ob- 
tained from New ‘England Nuclear (Boston, MA) and diluted with 
unlahellcd CMP-NeuAc 1231 to the desired specific activity. CMP- - _ _ . 
NeuAc:Gal,&-t4GlcNAc~R- a2-t6-sialyltransfensc (a6-sialyltrans- 
ferasc) was partially purified from bovine culostrum as dcscribcd 
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previously 1241. Asialo-a,-acid [‘H]glycoprorcin, specific;tlly labelled 
in the terminal Gal residues, was prepared as described [17]. Human 
liver obtained by autopsy of subjects that had died from non-liver 
disease and human placenta frozen directly after delivery were 
t,i’ovided by the Departments of Pathology and Gynaccology and 
Obstetrics, Academic Hospital of the Vrijc Universiteit, Amsterdam. 
Microsomal fractions were prepared from these tissues us described 
previously [ 16, I7:. The pcntasnccharidc. Gt11~1+4GlcNAc 
~1-+2Manal-1GMa1~144GlcNAc [22], wus generously donated by 
Drs. G. Streaker and J.C. Michalski (Univcrsitb de Like, Villcneuvc 
d’Ascq, France), and the trimethylgalactose standards were kindly 
supplied by Drs. P. and A. Stoffyn (Shrivcr Center, Waltham, MA), 
50% (w/w) ?&OH solution (low in carbonate) was purchased from 
Baker (Phillipsburg. NJ). 
fncubat&s of nsialo-x,-acid pH]glycoprotcin and CMP-NeuAc 
with human liver or human placenta microsomes (26 und 8 mg of 
protein, respectively) were performed as described previously [l6], 
After isolation, the sialylatcd products were digested by pronasc and 
the resulting -‘H-labelled glycopeptides were iso!ated by Dowex 50X- 
16 (H’) chromatography [I ‘I]. Methylation of the glycopeptidcs was 
performed as described [i6*25]. The methylated materials were subse- 
quently hydrolped in 400,ul of? M trifluaroacetic acid for GO min at 
120°C. After counting. appropriate aliquots (S-15 ~1) containing IOO- 
200 nCi of ‘H were spotted together with a mixture oftrimethylgalac- 
tose rcfcrcnces on Silica Gel 60 plates (IMerck, Darmstadt), Chroma- 
tograms were dcvcloped with acetone/cl.5 M NH,OH (500:9) us o 
solvent system [26’!. Radioactive compounds were detected by Ruo- 
rography, and reference-methylated galacloses were visualized with 
aniline ph!halate. 
Incubation mixtures contained in a volume of 50 yl: 50 nmol 
Gal~I~4GlcNA~1-~2Manal~6Manpl44GIcNAc, 25 nmol 
CMP-[3H]NeuAc (4.1 Ci/mol), 50ymol of sodium cacodylate. pH 6.7, 
50 nl Triton X-100 and either liver or placenta microsomes (1 and 3 
mg of protein, respectively). The mixtures wcrc incubated at 37°C for 
3 h, whereafter the incubations (verc stopped by cooling on ice. After 
the addition of 500~1 ice-cold H:O, the mintures wcrc centrifuged for 
I5 min in an Eppcndorf centrifuge at maximal speed. Pellets were 
washed twice with 700 AI ice-cold H1O and the pooled supernalant 
fractions were applied to a column (0.7 x 45 cm) of Bio-Gel P-4 
(2OO-400 mesh) equilibrated and eluted with 50 mM ammonium ece- 
tate at pH 5.2 and room tempertrture, at a flow rde or I5 ml/h. 
Fractions(0.7 ml) were collected and “H radioactivity was determined 
by iiquid scintillation counting. The sialylated products were pooled 
and lyophilized. 
The a6-sialylnted derivative of Gal/l -~4GlcNAc/?l -&Man 
al *6Man/Jl-+4GlcNAc was synthesized using bovine colosvum a6- 
sialyltransferase (190 /rU) as described [2,77]. The a3-sialylated ana- 
logue was produced using human placenta microsames (30 mg of 
prolcin) as a source of a3-sialyltransfcrasc in a ten-fold scaled up 
incubation. The products were isolated as described above. Character- 
ization of the latter product was by 400 MHz IH NMR spectroscopy 
after treatment of the sample with D20 1281. 
2.5. HPAEC-P/ID of sidylured oligosncciturirk prodrcfs 
The system used for HPAEC-PAD consisted of a Dioncx &o-i-C 
gradient pump, CarboPac PA-I column (4.0 x 250 mm) xnd a Model 
PAD 2 detector. The following pulse poicntials and durations were 
used for detection: E, = 0.05 V (I, = 480 ms): Ez = 0.60 V (f2 = I20 
ms); & = -0.60 V (tj = 60 ms). The response time of the detector was 
set to I s. Samples were dissolved in the cluan t mixture (see below) and 
injected via a Dioncx Micra Injection valve equipped with a 25 ,ul 
sample loop. The chromotographic data wcrc integrated and plotted 
using a Shim&u C-RSA integrator. A Dionex Eluant Degas Module 
was employed IO saturate the eluants with lrclium in order to de-gas 
and to minimize absorption of CO?. For the separation of the prod- 
ucts, isocratic elusion conditions wore employed using 0.2 M NaOHI 
1 M sodium acetate/H,0 (50:4:46, by vol,) as an eluant system, at a 
flow rate of I ml/min. Fractions of 0.5 ml were collected and counted, 
and the incorporation ofI”H]NcuAc was calculated from the radioac- 
tivity in the fractions containing the products. 
3. RESULTS 
Methylation analysis of the product obtained by in- 
cubating asiala-q-acid [3H]glycoprotein and CMP- 
NeuAc with human liver microsomes yielded a spot of 
2,3,4-trimethyl-[“Hlgalactose as the only trimethylated 
sugar (Fig:. 1, lane a). No such spot was detected when 
the product of sialylation was digested with neuram- 
inidase prior to methylation or when heat-inactivated 
microsomes were used (Fig. 1, lanes b and c). This 
indicates that by this method absialyltransferase is the 
only activity that can be detected in human liver. With 








Fig. I. Thin layer chromatography ofmethylated galactoses. Mcthyl- 
ated “H-labelled galacloses were derived from asialo-a,-acid 
[“Hlglycoprotcin sialylated in vitro by: (a) human liver micrasomes; 
lb) human liver microsames follow~ti by neuraminidase treatment; (c) 
heat-inactivuted human liver microsomcs; (d) human placenta micro- 
somes. The migralion of the following references is indicated: (1) 
tetramethylpalectosc; (2) 2,3,6-trimcthylgnlnctose; (3) 2,4,6-trimeth- 
ylgalactose; (4) 2,3.4-trimethylgalactosc; (5) 3,4,6-trinutl~ylgalactose. 
‘H-Labelled compounds were detcctcd by fluorography, and reference 
methylaud galacloses by aniline phthalatc. 
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H-l Gal l-l-3e NcuAc l-l-3a NeuAe 
I 1 1 1 , 
It.29s 
I -_I 
4.25 4.50 4.45 2.73 2.70 2.69 IS0 1.75 1.70 
15 cppm 
Fig. 2. Characteristic resonance patterns of the galaclose H-l atoms 
and of the NcuAc H-3e and H-3a protons in the 400 MHz ‘H NMR 
spectrum ofGal~lTulGlcNAc~l_pZMa11a1-t6(3)Man~l~4GlcNAc 
a3-sialylated using human placenta microsomcs. In addition to the 
signals of the above mentioned protons of the a%3-sialybdted pen- 
tasaccharide. the positions of the resonances of its Cr2--P6-sialylatcd 
isomer and of the asialo substrdtc (H-l of Gal) are indicated. -l-he 
asterisk dcnotcs an impurity. 
shown). By contrast, the incubation with placental mi- 
crosomes yielded a product that resulted in a spot of 
2,4,6-trimethyl-[3H]galactose uponmethylation (Fig. 1, 
lane d), confirming that this tissue contains an active 
a3-sialyltransferase. 
In all instances, upon prolonged exposure of the 
Ruorograms, weak spots could be seen on each trimeth- 
ylgalactose position. Although it cannot be excluded 
that these spots reflect low levels of other sialyltrans- 
ferases, they are most likely due to some undermethyla- 
tion or to de-methylation of tetramethylgalactose dur- 
ing acid hydrolysis [16]. 
Examination of the 400 MHz ‘H NMR spectrum of 
the oligosaccharide used as a substrate in the sialylation 
reactions showed this material to consist of 
Ga~l~4GlcNAc~l+2Manal+6Mun~1~4GlcNAc 
as a major compound with some (9%) contaminating 
Gal,& ~4GlcNAc~1+2Man~l~3Man~l~4GlcNAc 
(data not shown). Analysis of the product isolated from 
the incubation with placenta microsomes as a prepara- 
tion of a3-sialyltransferase appeared to contain only 
a2+3-linked NeuAc (H-3eq NeuAc S = 2.757 ppm; 
H-3ax NeuAc 6 = 1.798 ppm; NAc NeuAc S = 2.031 
ppm; H-l Gal 6 = 4.547) [29]. No indication for the 
presence of a2+6-linked NeuAc in this product was 
apparent from the spectrum (Fig. 2). The a2+6-sialyl- 
ated pentasaccharide, NeuAca2+6Gal/?1+4GlcNAc 
/31+2Manal+6Man/31+4GlcNAc, was obtained 
using the well-defined Galp 1+4GlcNAc-R a2+6-sia- 
lyltransfcrase from bovine colostrurn, which was 
proven to catalyze the addition of NeuAc into 
Gal,81+4GlcNAc-structures in a2+6-linkage exclu- 
sively [2,27,28]. 
Fig. 3. HPAEC-PAD profiles of the products of sialyltmnsfcrases 
using Gal~I+4GlcNA~I~?ManaI+G(3)Man~l+4GlcNAc as ac- 
ceptor substrutc. Elution of (A) rcfercncesobtaincd with bovinccolos- 
trum adsialyltransferasc and human placenta microsomcs as a source 
of a3-sialyltrdnsferase. (B) the products of incubation of with humnn 
liver microsomes, and (C) the products obtained with human placenlii 
microsomcs. The elution positions of the following rcfcrences arc 
indicated: (I) Gal~l+4GlcNAt$l-ZManal~GMan~l-+4GlcNAc: 
(2) NcuAc; (3) NeuAcaP+CiGa~l-+4GlcNAc~l -QManzl+ 
6Mz?9l_rlGlcNAc; (4) NeuAca2-~3Ga~l+lGl~NA~l-L! 
Manol~6Man~l+4GlcNAc. lsocrdtic clution with 0.20 M NaOH/ 
1.00 M sodium acetate/water (50:4:46, v/v) was carried oul as dc- 
Using HPAEC-PAD, elution conditions were elabo- scribed in Materials and Methods. The flow rate was I ml/min. 
rated by which baseline separation of!he reference com- 
pounds, NeuAcaZ+ 6GaJ/Il +IGlcN_&$?l +2Manal+ 
6Man,8 1+4GlcNAc and NeuAca2+3Gal/31+ 
4GlcNAc/? I +2Mana 1 -+BMa@1+4GlcNAc, was ob- 
tained (Fig. 3A). These materials also separated well 
33 
Volume 312, number 1 FEES LETTERS November 1992 
Table I 
Ratios ofsidlylatcd products as detected by HPAEC-PAD 
Products Sormed Retention time 
(min) 
Ratio (‘hb) of products 
formed with 
Human liver Human placenta 
NeuAca2-t6Gal/YI+4GlcNAc@l-QMan~I+5M~n~I-34Gl~NA~ 15.6 69.4 2.5 
NeuAca2~3Gal~I-t4GlcNA~1~2Man~l~6Man~1+4GlcNAc 17.8 13.1 76.9 
NeuAca2~(iGalpI+4GlcNAc@1~2ManzI+3Man~l+4GlcNAc 20.5 14.4 <CL8 
NeuAcz2~3Gal,L?1+4GlcNAc,81~2M;maI-~3Man~I-+4GlcNAc 21.9 3.1 20.5 
Gal~l+4GlcNAc,81-L!Manal-36Man/?l-+4GlcNAc was sialylated using CMP~[“H]NcuAc and human liver or human placenta microsomcs as 
described in Materials and Methods. The products were separated using HPAEC-PAD and their relative amounts were estimated by liquid 
scintillalion counting. 
from the oligosaccharide substrate and NeuAc. Two 
satellite peaks could be observed which most likely rep- 
resent the a6- and cc3-sialylated erivatives of 
Gap1 +4GlcNA$1+2Manal +SMan/31+4GlcNAc, 
respectively, which are formed from the minor oligosac- 
charide isomer in the substrate. It is noteworthy that 
a6-sialylated compounds and oligosaccharides, con- 
taining a Manal_pGMan linkage, elute earlier than the 
isomers having an a3-linkage, since this order is oppo- 
site to that obtained by HPLC on amino-bound silica 
columns [21,30,3 11. 
HPAEC-PAD analysis of the products of sialylation 
obtained with human liver microsomes showed that sev- 
eral sialylated oligosaccharides were folmed (Fig. 3B). 
The major (retention time 15.6 min) and the minor peak 
(20.5 min) could be identified as a2+6-sialylated prod- 
ucts, together comprising ~80% of the total sialylated 
products (Table I). In addition, minor amounts of 
a2-+3-sialylated oligosaccharides (-20%) could be de- 
tected, with retention times of 17.8 and 21.9 min, rcspec- 
tively (Fig. 3B). By contrast, the incubation with human 
placenta microsomes was found to yield mainly a2+3- 
sialylated products (retention time 17.8 and 21.9 min) 
(Fig. 3C), along with distinct trace amounts (~3%) of 
cr6-sialylated product (Table I). 
4. DISCUSSION 
A characteristic structural feature of the di-antennary 
N-acetyllactosamine type &cans of glycoproteins yn- 
thesized by the human li.ver is the predominant occur- 
rence of ~~296 terminally linked sialic acid [l]. By con- 
trast, the tri- and tetra-antennary glycans of these 
glycoproteins have been shown to contain not only 
a2+6- but also cc2+3=linked sialic acid (references cited 
in [2,3]). Different methods have been employed to de- 
tect the human liver a3-sialyltransferase responsible for 
the synthesis of the a2+Zsialylated glycans. However, 
only a6-sialyltransferase and no a3-sialyltransferase ac- 
tivity was found in this tissue using Galpl-+4GlcNAc 
as an acceptor followed by HPLC analysis of the prod- 
ucts [2 11, nor could we detect a3-sialyltransferase activ- 
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ity by methylation analysis using asialo-al-acid 
[“Hlglycoprotein as an acceptor (this study). Moreover, 
purification of a Ga~l+4GlcNAc-R specific sia- 
lyltransferase from human liver yielded a preparation 
which did not contairi a3-sialyltransferase activity [33]. 
However, using the pentasaccharide, GalpI +AGlcN-AC 
b1+2Manal +BManpl +IGlcNAc, as an acceptor 
substrate in the incubation with human liver micro- 
somes and employing HPAEC-PAD for the separation 
of the a2-+3- and a2+6-sialylated oligosaccharide 
products, we were able to detect a distinct amount of 
a2+3-sialylated material. This indicates that an a3- 
sialyltransferase, capable of sialylating Ga1/3I+ 
LEGlcNAc-R acceptor structures, is indeed present in 
human liver in addition to the more abundant #6-sia- 
lyltransferase. This is the first report of such an enzyme 
in this tissue. 
The failure to detect his a3-sialyltronsferase activity 
with N-acetyllactosamine as an acceptor [21] is proba- 
bly due to the poor acceptor property of this disaccha- 
ride for the cr3-sialyltransferase relative to that for the 
a6-enzyme [20]. Apparently the pentasaccharide used in 
this study is a much better acceptor substrate in this 
respect. In addition, the larger size of the products in the 
latter case, as well as the HPLC system used, make it 
easier to separate these materials from the excess of 
CMP-NeuAc, resulting in a better signal-to-noise ratio. 
The human liver a3-sialyltransferase might be similar 
to the previously reported Galpl+3(4)GlcNAc-R 
cr2+3&lyltransferase from rat liver [l&20], which 
was found to preferentially act on type 1. 
Gal,Bl+3GlcNAc-R termini, but which can also cata- 
lyze the sialylation of Galp1+4GlcNAc-R (type 2) gly 
cans, albeit with low efficiency [20]. It can not be ex- 
cluded, however, that the human liver a3-sialyltrans- 
ferase has a greater preference for type 2 acceptor 
chains. Type 1 chains have been described on glycopro- 
teins from rat plasma [33], but up until now not on 
human serum glycoproteins. On the other hand it is 
highly improbable that the a3-sialyltransferase activity 
is due to the action of a Gal,&I+3GalNAc-R aZ->3- 
sialyltransferase which generally occurs in liver tissue 
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and is most likely present also in human liver [34]. Duri- 
ficd preparations of this enzyme from porcine submax- 
illary gland [35], human placenta [3G] and porcine liver 
[37] show virtually no activity with Galpl-4GlcNAc 
type acceptors. 
It was interesting to find, in addition to the major 
a3-sialylated products, a small but distinct amount of 
a2+6-sialylated pentasaccharide as a product from the 
incubation with human placenta microsomes. This re- 
sult was even more surprising sinw prior analysis of this 
sialylated material by 400 MHz ‘H NMR spectroscopy 
did not reveal NeuAc linkages other than &!-+3. In 
addition, methylation analysis of the product obtained 
with placenta microsames using asialo-q-acid 
[3H]glycoprotein as an acceptor did not yield indications 
for an a2+&sialic acid transfer either. Based on iikr 
latter results and on structural data of sialylated 
glycoprotcins from placental origin (e.g. human cbori- 
onic gonadotropin [10,38-40], human P-glucocerebro- 
sidase [41] and human transferrin receptor [42]), reveal- 
ing the exclusive presence of a3-linked NeuAc, the 
a2-+6+ialyltransferase capable of synthesizing 
NeuAca2+6Gal,S1+4GlcNAc-R structures was 
thought to be absent in human placenta. However, 
more recently acid a-glucosidase from human placenta 
was found to contain very small amounts of a2+6- 
sialylated diantennary N-acetyllactosamine type gly- 
cans [43]. Although other (N-acetyllactosaminide and 
IV-acetylglucosaminide) crG-sialyltransferases have been 
detected in this tissue [19,44], none of these are able to 
act on Gal,01+4GlcNAc-R structures. Therefore the 
a2+6-sialylated pentasaccharide product reflects the 
presence of a Gal/31 +4GlcNAc-R specific a2+6-sia- 
lyltransferase in this tissue. We therefore expect hat 
other IV-acetyllactosamine type glycoproteins from 
human placenta may also contain small amounts of 
a2+6-linked sialic acid. 
Finally we conclude that HPAEC-PAD is a conven- 
ient method to resolve and sensitively detect small 
amounts of sialylated oligosaccharide isomers. In com- 
bination with appropriate acceptor substrates, this 
method can be used to reveal the presence of specific 
sialyltransferases that cannot be detected by methyla- 
tion analysis or high resolution ‘H NMR spectroscopy, 
because of the higher detection limits of the latter two 
methods. 
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